TAR-210

Phase 3Small molecule

TAR-210 is one of 3 small molecule programs targeting Non-Muscle Invasive Bladder Neoplasms. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Muscle Invasive Bladder NeoplasmsRecruiting

Non-Muscle Invasive Bladder NeoplasmsPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Non-Muscle Invasive Bladder Neoplasms

#DrugCompanyPhaseTrials

TAR-200

Johnson & Johnson

Phase 3

2 2

TAR-210

Johnson & Johnson

Phase 3

1 3

Balversa

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 3Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06919965

Clinical

Trials by Indication[1]

Non-Muscle Invasive Bladder Neoplasms1 trial

A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06919965·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAR-210. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAR-210 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAR-210. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

TAR-210

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Non-Muscle Invasive Bladder Neoplasms1 trial

References

Drug Info

Quick Facts

Related News